Parallax Volatility Advisers’s Intellia Therapeutics NTLA Stock Holding History

Parallax Volatility Advisers’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-400	Closed	-$14.9K	–	2740
2023 Q1	$14.9K	Hold	400	–	–	﹤0.01%	2355
2022 Q4	$14K	Sell	400 -74,600	-99%	-$3.55M	﹤0.01%	2526
2022 Q3	$4.2M	Buy	75,000 +74,900	+74,900%	+$4.65M	0.01%	1095
2022 Q2	$5K	Buy	+100	New	+$5.08K	﹤0.01%	2726
2021 Q4	–	Sell	-27,600	Closed	-$3.7M	–	3301
2021 Q3	$3.7M	Sell	27,600 -10,000	-27%	-$1.51M	﹤0.01%	1368
2021 Q2	$6.09M	Buy	+37,600	New	+$2.93M	0.01%	1113
2020 Q4	–	Sell	-35,800	Closed	-$712K	–	3445
2020 Q3	$712K	Buy	+35,800	New	+$746K	﹤0.01%	2125
2018 Q3	–	Sell	-17,700	Closed	-$483K	–	3253
2018 Q2	$483K	Buy	+17,700	New	+$429K	﹤0.01%	1280

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallax Volatility Advisers's NTLA Position: Q4 2024 in Review

Parallax Volatility Advisers sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 35,994 shares — an estimated $740K sold.

Parallax Volatility Advisers first reported a position in NTLA in Q4 2017 and held it in 10 quarters. The position peaked at $4.66M in Q2 2021. 295 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

Parallax Volatility Advisers reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
Parallax Volatility Advisers sold 35,994 Intellia Therapeutics shares in Q4 2024, an estimated $740K.
Parallax Volatility Advisers first reported a position in Intellia Therapeutics in Q4 2017 and held it in 10 quarters.
Parallax Volatility Advisers's Intellia Therapeutics position peaked at $4.66M in Q2 2021.
295 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Parallax Volatility Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.